Bristol-Myers Squibb Foundation Awards $2.34 Million in Grants to Help Prisoners with Mental Illness Return to Community

Mental Health & Well-Being initiative partners with South Florida Behavioral Health Network and Valley Cities Counseling to stop vicious cycle of arrest, release and relapse

NEW YORK--(BUSINESS WIRE)-- The numbers are sobering: more than two million arrests in the United States each year involve people with serious mental illnesses (SMI). By the best and most recent estimate, nearly one in three women and one in seven men in our nation’s jails suffer from depression, bipolar disorder, schizophrenia or other mental illnesses.

For these individuals, finding work and a place to live – already difficult due to their criminal record – is complicated by their mental illnesses or behavioral health issues such as drug or alcohol addiction. Without effective treatment, their lives can become a vicious cycle of arrest, release, homelessness and relapse.

Recognizing the enormous challenges they face, the Bristol-Myers Squibb Foundation today announced grants to two community partners that will help people with SMI involved in the criminal justice system successfully return to society:

  • South Florida Behavioral Health Network (SFBHN) will receive $1.23 million over three years to develop, implement and evaluate a first-of-its-kind Coordinated System of Care for individuals with SMI in the criminal justice system in Miami-Dade County, Florida. SFBHN will partner with the Miami-Dade Chapter of Florida Partners in Crisis, the 11th Judicial Circuit Criminal Mental Health Project, the Florida Mental Health Institute at the University of South Florida and the American Psychiatric Foundation to bring a coordinated, evidence-based approach to mental health services for individuals who experience chronic and persistent SMI, and who demonstrate moderate to high risk of ongoing involvement in the justice system and acute care settings.
  • Valley Cities Counseling and Consultation will receive $1.11 million over two years to develop, implement and evaluate a Forensic Mental Health Peer Support program designed to decrease recidivism among adults convicted of misdemeanors and address the re-entry needs of people with SMI who are leaving the local jail in King County, Washington. Valley Cities will train peer specialists with histories of mental illness and criminal justice system involvement to help others with similar experiences. Based on the fact that two-thirds of the high users of King County jails are adults with SMI, and two-thirds of these individuals are detained for misdemeanors and non-violent felonies, developing community support programs that keep these individuals out of jail is a key priority. The peer support program will provide these individuals with practical assistance and a support system that will help them successfully return to their community and stop cycling through the justice system. Valley Cities will be the first to fully develop a curriculum and evaluate the outcomes of the Forensic Peer Support Model, which could serve as an evidence-based resource used in city and county jails across the country.

“Individuals with serious mental illness are twice as likely to fail on traditional community supervision compared with individuals without mental illness, and there are few existing community supports tailored to the unique needs of this vulnerable population,” says John Damonti, president, Bristol-Myers Squibb Foundation and vice president, Corporate Philanthropy, Bristol-Myers Squibb. “These individuals need a safety net. By providing them with support and tools to avoid another crisis and progress toward their recovery goals in the community, we hope to stop this downward spiral.”

As the number of people with SMI who are incarcerated across the United States has grown, mental health advocates such as the National Alliance on Mental Illness (NAMI) and others have, for years, been demanding better treatment of this population. Over the past 50 years, the number of psychiatric hospital beds in the U.S. has decreased 90 percent while the number of people with mental illness in prisons and jails has increased 400 percent. This leads us to the current reality where today more Americans with mental illnesses are treated in correctional facilities than in psychiatric hospitals; a situation that has significant financial and social ramifications across the country.

Florida, for example, spends about $600 million a year – $1.6 million per day – to house people with mental illness in state prisons and forensic treatment facilities. The Miami-Dade County Jail is the largest psychiatric institution in Florida, spending an estimated $60 million each year to house people with mental illnesses.

One in seven males (14.5 percent) and three in 10 females (31 percent) serving time in the Miami-Dade jail experience serious mental illnesses. Among those who are the heaviest users of mental health care, the typical inmate in the Miami-Dade jail has been arrested 22 times over the past five years and spent 275 days behind bars during that period.

About the Bristol-Myers Squibb Foundation

The Bristol-Myers Squibb Foundation is an independent 501(c)(3) charitable organization whose mission is to reduce health disparities and improve health outcomes around the world for patients disproportionately affected by serious disease. You can learn more about the Foundation at http://www.bms.com/foundation.



CONTACT:

Bristol-Myers Squibb
Ken Dominski, 609-252-5251
[email protected]

KEYWORDS:   United States  North America  New York

INDUSTRY KEYWORDS:   Health  Mental Health  Pharmaceutical  Philanthropy  Foundation

MEDIA:

Logo
 Logo

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.